IL4-10 synerkine also showed a reducing effect on the release ... suggest that the synerkine is an effective disease modifying drug in the treatment of osteoarthritis.

Together with the pain inhibiting effects found in animal models of OA, these data suggest disease modifying characteristics of the IL4-10 synerkine. Van Roon JA, Lafeber FP, Bijlsma JW. (2001).

The US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults with bullous pemphigoid (BP).